.webp?width=100&height=76&name=icons%20(1).webp)
.webp?width=100&height=76&name=Layer_1%20(1).webp)
.webp?width=100&height=76&name=Layer_1%20(2).webp)
.webp?width=100&height=76&name=Vector%20(2).webp)
.png?width=100&height=76&name=Layer_1%20(1).png)
.webp?width=100&height=76&name=Layer_1%20(4).webp)
.webp?width=100&height=76&name=Layer_1%20(3).webp)
-1.webp?width=100&height=76&name=Layer_1%20(2)-1.webp)
March 23-26, 2026
New York City
What has shaped our journey
The company we are today was built through a consistent focus on quality, expertise, and long-term partnership.
Technical Rigor
A disciplined, science-based approach has shaped our work from the beginning.
Long-Term Partnership
We have grown by building lasting relationships and supporting clients through evolving needs.
Driven by Quality
A quality mindset central to how we develop and manufacture pharmaceutical products.
Purposeful Growth
Each step forward is taken based on decisions that strengthen our capabilities over time.
Groupe Parima over the years
From our early packaging operations to a fully integrated CDMO, each step reflects a deliberate expansion of our capabilities.
-
1994
A Vision Rooted in Operational Reliability
Claude Mongrain, our founder, set out to build a company focused on delivering meaningful, value‑added services. Groupe PARIMA began with primary and secondary packaging services, laying the foundation for the technical expertise and operational capabilities that define our organization today.
-
1996
The Beginning of Global Reach
Groupe PARIMA completed its first pharmaceutical product shipments outside of Canada, marking a key milestone in the company’s international growth and expansion into global markets.
-
2000
Expanded Facilities and Capabilities
Groupe PARIMA relocated to a modern facility designed to support a full range of manufacturing and packaging services. This move also marked the addition of an in‑house laboratory, strengthening our technical capabilities and operational autonomy.
-
2002
Expanding into Product Development
Groupe PARIMA launched its pharmaceutical product development services, marking a strategic expansion of our capabilities and a new stage in the evolution of our technical expertise.
-
2015
Transition in the company’s Leadership
Louis‑David Cantin was named President and became co‑owner of Groupe PARIMA, opening a new chapter focused on continuity, innovation, and growth.
-
2024
Ownership Transition and Long‑Term Continuity
Groupe PARIMA reaffirmed its long‑term ownership under Louis‑David Cantin, ensuring continuity in its mission, values, and strategic direction. Built on strong foundations, the organization continues to evolve while remaining deeply rooted in its original vision.
CONTACT US
Explore Our
Capabilities
Discover how our experience can support your drug product at every stage of its lifecycle.